Onarae V. Rice
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Onarae V. Rice has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Charles R. Ashby
Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions St. John's University Jamaica New York 11439
2 shared publications- Eliot L. Gardner
National Institute on Drug Abuse, USA
2 shared publications - Amit Kumar Tiwari
Department of Pharmaceutical Sciences, College of Pharmacy University of Arkansas for Medical Sciences Little Rock Arkansas USA
1 shared publication Charles A. Schonhar
Psychology Department Furman University Greenville South Carolina 29613
1 shared publicationCharles D. Schonhar
Psychology Dept., Furman University, 3300 Poinsett Highway, Greenville, SC 29613
1 shared publication- Charles R AshbyJr
Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA
1 shared publication
Latest Publications
- Open Access
Selective dopamine D3receptor antagonism significantly attenuates stress‐induced immobility in a rat model of post‐traumatic stress disorder
Post‐traumatic stress disorder (PTSD) is a debilitating psychiatric syndrome that occurs in individuals exposed to extremely threatening or traumatic events. In both animals and humans, dopamine (DA) function appears to be dysregulated in brain areas involved in the conditioned fear response(s) that underlie PTSD. In this study, we determined the effect of the selective DA D3receptor antagonists YQA14A (6.25, 12.5 and 25 mg/kg i.p.) and SB‐277011A (6 mg/kg i.p.) on tone‐induced fear (assessed by measuring freeze time) in a modified version of the single‐prolonged stress (SPS) model of PTSD in adult male Sprague‐Dawley rats. Rats pretreated with vehicle and then subjected to restraint stress, forced swim and random foot shock (SPS) in the presence of a distinctive tone, displayed a significantly increased tone‐induced contextual freeze time and fecal pellet mass following re‐exposure to the tone. Rats pretreated with a single i.p. injection of 6.25 or 12.5 mg/kg of YQA14 or 6 mg/kg of SB‐277011A showed significantly attenuated contextual freeze time in the presence of the tone when tested 14 days after exposure to SPS. Overall, our results indicate that selectively antagonizing DA D3receptors significantly decreases freezing time caused by an environment previously associated with stress. If our findings can be extrapolated to humans with PTSD, they suggest that DA D3receptors may play a role in the pathophysiology of PTSD, and may have therapeutic utility for the clinical management of PTSD.
Open AccessSelective dopamine D3receptor antagonism significantly attenuates stress‐induced immobility in a rat model of post‐traumatic stress disorder
Post‐traumatic stress disorder (PTSD) is a debilitating psychiatric syndrome that occurs in individuals exposed to extremely threatening or traumatic events. In both animals and humans, dopamine (DA) function appears to be dysregulated in brain areas involved in the conditioned fear response(s) that underlie PTSD. In this study, we determined the effect of the selective DA D3receptor antagonists YQA14A (6.25, 12.5 and 25 mg/kg i.p.) and SB‐277011A (6 mg/kg i.p.) on tone‐induced fear (assessed by measuring freeze time) in a modified version of the single‐prolonged stress (SPS) model of PTSD in adult male Sprague‐Dawley rats. Rats pretreated with vehicle and then subjected to restraint stress, forced swim and random foot shock (SPS) in the presence of a distinctive tone, displayed a significantly increased tone‐induced contextual freeze time and fecal pellet mass following re‐exposure to the tone. Rats pretreated with a single i.p. injection of 6.25 or 12.5 mg/kg of YQA14 or 6 mg/kg of SB‐277011A showed significantly attenuated contextual freeze time in the presence of the tone when tested 14 days after exposure to SPS. Overall, our results indicate that selectively antagonizing DA D3receptors significantly decreases freezing time caused by an environment previously associated with stress. If our findings can be extrapolated to humans with PTSD, they suggest that DA D3receptors may play a role in the pathophysiology of PTSD, and may have therapeutic utility for the clinical management of PTSD.
The selective dopamineD3receptor antagonistSB‐277011‐Asignificantly decreases binge‐like consumption of ethanol inC57BL/J6 mice
The authors show that the dopamine D3 antagonist SB‐277011‐A consistently and persistently decrease binge‐like EtOH consumption at 30 mg/kg and it decreases binge‐like consumption on days 3, 7, 9, and 11–13 at 15 mg/kg. These findings suggest that the brain's D3 receptor may also be involved in not only ethanol reward but binge drinking as well.Synapse 69:295–298, 2015.
The selective dopamineD3receptor antagonistSB‐277011‐Asignificantly decreases binge‐like consumption of ethanol inC57BL/J6 mice
The authors show that the dopamine D3 antagonist SB‐277011‐A consistently and persistently decrease binge‐like EtOH consumption at 30 mg/kg and it decreases binge‐like consumption on days 3, 7, 9, and 11–13 at 15 mg/kg. These findings suggest that the brain's D3 receptor may also be involved in not only ethanol reward but binge drinking as well.Synapse 69:295–298, 2015.
The effects of the preferential dopamine D3 receptor antagonist S33138 on ethanol binge drinking in C57BL/6J mice
The mesolimbic dopamine (DA) pathway plays an integral role in the reinforcing properties of many drugs of abuse, including alcohol (ethanol/EtOH). It has been reported that selective and acute blockade of the DA D3 receptor by SB‐277011A will attenuate EtOH preference, intake, and lick responses in EtOH preferring rats. However, alcohol consumption that leads to abuse is often marked by binge drinking—which is characterized as bringing ones blood EtOH levels to ≥80 mg/dL within 2 hours of the initial drink. It is unclear if brain mechanisms implicated in EtOH reward are equally implicated in EtOH binge consumption and abuse. Therefore, in this study, we examined the effect of the preferential D3 receptor antagonist S33138 on ethanol (6% v/v) and water consumption in male C57BL/6J mice using a restricted‐access binge‐drinking model. Ethanol drinking was not significantly altered by the intraperitoneal (i.p.) administration of 0.16 mg/kg of S33138. In contrast, the i.p. administration of 0.64 or 2.5 mg/kg i.p. of S33138 produced a significant decrease in ethanol consumption on days 1 and 7 and days 7–14 compared to vehicle treated animals. However, the mean water consumption was significantly decreased by (1) 0.16 and 0.64 mg/kg i.p. of S33138 on Day 1 and (2) 2.5 mg/kg i.p. of S33138 at Days 1, 7, and 7–14. Our studies indicate that a low dose of S33138 significantly decreases binge drinking, and that it does not significantly alter the consumption of water. In addition, S33138 alone is not appetitive. Synapse 66:975–978, 2012.
The effects of the preferential dopamine D3 receptor antagonist S33138 on ethanol binge drinking in C57BL/6J mice
The mesolimbic dopamine (DA) pathway plays an integral role in the reinforcing properties of many drugs of abuse, including alcohol (ethanol/EtOH). It has been reported that selective and acute blockade of the DA D3 receptor by SB‐277011A will attenuate EtOH preference, intake, and lick responses in EtOH preferring rats. However, alcohol consumption that leads to abuse is often marked by binge drinking—which is characterized as bringing ones blood EtOH levels to ≥80 mg/dL within 2 hours of the initial drink. It is unclear if brain mechanisms implicated in EtOH reward are equally implicated in EtOH binge consumption and abuse. Therefore, in this study, we examined the effect of the preferential D3 receptor antagonist S33138 on ethanol (6% v/v) and water consumption in male C57BL/6J mice using a restricted‐access binge‐drinking model. Ethanol drinking was not significantly altered by the intraperitoneal (i.p.) administration of 0.16 mg/kg of S33138. In contrast, the i.p. administration of 0.64 or 2.5 mg/kg i.p. of S33138 produced a significant decrease in ethanol consumption on days 1 and 7 and days 7–14 compared to vehicle treated animals. However, the mean water consumption was significantly decreased by (1) 0.16 and 0.64 mg/kg i.p. of S33138 on Day 1 and (2) 2.5 mg/kg i.p. of S33138 at Days 1, 7, and 7–14. Our studies indicate that a low dose of S33138 significantly decreases binge drinking, and that it does not significantly alter the consumption of water. In addition, S33138 alone is not appetitive. Synapse 66:975–978, 2012.
- Open Access
The acute administration of the selective dopamine D3receptor antagonist SB‐277011A reverses conditioned place aversion produced by naloxone precipitated withdrawal from acute morphine administration in rats
We examined the effect of SB‐277011A, a selective D3receptor antagonist, on the conditioned place aversion (CPA) response associated with naloxone‐induced withdrawal from acute morphine administration in male Sprague‐Dawley rats. Morphine (5.6 mg/kg i.p.) was given, followed 4 hrs later by naloxone (0.3 mg/kg i.p.) and prior to placing the animals in one specific chamber of the test apparatus. All animals were subjected to 2 of these trials. A significant CPA occurred in animals that received an i.p. injection of vehicle 30 minutes prior to the measurement of chamber preference. The pretreatment of animals (30 minutes prior to testing) with 3 mg/kg i.p. of SB‐277011A did not significantly alter the CPA compared to animals treated with vehicle (1 ml/kg i.p. of deionized distilled water). In contrast, the acute pretreatment of animals with 6, 12 or 24 mg/kg i.p. of SB‐277011A significantly decreased the CPA compared to vehicle‐treated animals. In fact, the 12 and 24 mg/kg doses of SB‐277011A significantly increased the time spent in the chamber where animals were paired with morphine and naloxone. These results suggest that the selective antagonism of D3receptors attenuates the CPA produced by a model of naloxone‐induced withdrawal from acute morphine dependence. Synapse, 2012.
Open AccessThe acute administration of the selective dopamine D3receptor antagonist SB‐277011A reverses conditioned place aversion produced by naloxone precipitated withdrawal from acute morphine administration in rats
We examined the effect of SB‐277011A, a selective D3receptor antagonist, on the conditioned place aversion (CPA) response associated with naloxone‐induced withdrawal from acute morphine administration in male Sprague‐Dawley rats. Morphine (5.6 mg/kg i.p.) was given, followed 4 hrs later by naloxone (0.3 mg/kg i.p.) and prior to placing the animals in one specific chamber of the test apparatus. All animals were subjected to 2 of these trials. A significant CPA occurred in animals that received an i.p. injection of vehicle 30 minutes prior to the measurement of chamber preference. The pretreatment of animals (30 minutes prior to testing) with 3 mg/kg i.p. of SB‐277011A did not significantly alter the CPA compared to animals treated with vehicle (1 ml/kg i.p. of deionized distilled water). In contrast, the acute pretreatment of animals with 6, 12 or 24 mg/kg i.p. of SB‐277011A significantly decreased the CPA compared to vehicle‐treated animals. In fact, the 12 and 24 mg/kg doses of SB‐277011A significantly increased the time spent in the chamber where animals were paired with morphine and naloxone. These results suggest that the selective antagonism of D3receptors attenuates the CPA produced by a model of naloxone‐induced withdrawal from acute morphine dependence. Synapse, 2012.